The introduction of “personalized medicine” has spurred major changes in oncology, but success has been spread unevenly across the spectrum of solid tumors. Although prognoses for adenocarcinoma of the lung and melanoma have been profoundly altered, other diseases, such as colon cancer and ovarian cancer, have lagged behind owing to differences in genetics and biology. One of the earliest classes of targeted therapies in ovarian cancer has been the PARP (polyadenosine diphosphate–ribose polymerase) inhibitors. 1-3 In this issue of the Journal , investigators report the results of three randomized trials of three different PARP inhibitors for maintenance therapy in patients with ovarian . . .